

Clinicopathologic characteristics and treatment of marginal mucosa-associated lymphoid tissue (MALT lymphoma)

Ca-A Cancer Journal for Clinicians

66, 152-171

DOI: [10.3322/caac.21330](https://doi.org/10.3322/caac.21330)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma). , 2008, , 513-520.		0
2	Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas. <i>Journal of Cancer</i> , 2016, 7, 1215-1225.	1.2	12
3	Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2239-2247.	1.2	33
4	18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. <i>Leukemia and Lymphoma</i> , 2017, 58, 2328-2334.	0.6	38
5	Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 118-130.	0.7	44
6	Pulmonary mucosa-associated lymphoid tissue lymphoma: ¹⁸ F-FDG PET/CT and CT findings in 28 patients. <i>British Journal of Radiology</i> , 2017, 90, 20170311.	1.0	42
7	An unusual cause of fever in a patient with common variable immunodeficiency. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 210-213.	0.5	1
8	The multiple faces of marginal zone lymphomas. <i>Hematological Oncology</i> , 2017, 35, 46-48.	0.8	3
9	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 130, 1772-1774.	0.6	60
10	Marginal zone lymphoma in elderly and geriatric patients. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 158-165.	0.7	8
11	18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 589-597.	3.3	51
12	A case of pulmonary MALT lymphoma with preoperative definitive diagnosis based on IgH rearrangement in paraffin-embedded specimen. <i>The Journal of the Japanese Association for Chest Surgery</i> , 2017, 31, 221-226.	0.0	0
13	Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. <i>Journal of Clinical Oncology</i> , 2017, 35, 1872-1878.	0.8	3
14	Primary Urinary Tract Lymphoma: Rare but Aggressive. <i>Anticancer Research</i> , 2017, 37, 6989-6995.	0.5	13
15	Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum. <i>Case Reports in Oncology</i> , 2018, 11, 239-245.	0.3	4
17	Primary spinal mucosa-associated lymphoid tissue lymphoma. <i>Medicine (United States)</i> , 2018, 97, e9329.	0.4	4
18	Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review. <i>Annals of Hematology</i> , 2018, 97, 821-829.	0.8	7
19	Effective management strategies for patients with marginal zone lymphoma. <i>Future Oncology</i> , 2018, 14, 1213-1222.	1.1	11

#	ARTICLE	IF	CITATIONS
20	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature. <i>Journal of Oncological Science</i> , 2018, 4, 56-59.	0.1	2
21	Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now. <i>European Radiology</i> , 2018, 28, 1187-1193.	2.3	22
22	Mucosa-associated lymphoid tissue lymphoma with intraocular and orbital involvement: case presentation and review of the literature. <i>Orbit</i> , 2018, 37, 243-247.	0.5	9
23	Overview on the management of non-gastric MALT lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 57-64.	0.7	41
24	Immunoglobulin G4 (IgG4)-Positive Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma and Idiopathic Orbital Inflammation. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, 313-319.	0.4	16
25	Association between <i>Helicobacter pylori</i> infection and Sjögren syndrome. <i>Medicine (United States)</i> , 2018, 97, e13528.	0.4	23
26	Primary Localized Esophageal Mucosa-associated Lymphoid Tissue Lymphoma Treated by Endoscopic Submucosal Dissection. <i>Internal Medicine</i> , 2018, 57, 2347-2352.	0.3	9
27	Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. <i>Cancer Control</i> , 2018, 25, 107327481877825.	0.7	98
28	Recent advances in treating extra-ocular lymphomas. <i>Expert Review of Ophthalmology</i> , 2018, 13, 205-217.	0.3	12
29	DWI-MRI vs CT in gastric MALT lymphoma—preliminary results in 19 patients. <i>British Journal of Radiology</i> , 2018, , 20180263.	1.0	3
30	A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Frontiers in Neurology</i> , 2018, 9, 267.	1.1	16
31	Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)—Real-world data from the Medical University of Vienna. <i>Hematological Oncology</i> , 2019, 37, 345-351.	0.8	11
32	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. <i>British Journal of Haematology</i> , 2019, 186, 448-459.	1.2	16
33	Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. <i>Molecular Imaging and Biology</i> , 2019, 21, 1192-1199.	1.3	11
34	Rare Multiple Lesions Arising in Small and Large Intestines. <i>Gastroenterology</i> , 2019, 156, e1-e3.	0.6	1
35	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 447-455.	0.4	31
36	Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results. <i>Annals of Hematology</i> , 2019, 98, 1675-1687.	0.8	12
37	Small bowel mucosa-associated lymphoid tissue lymphoma: A case report and literature review. <i>Advances in Digestive Medicine</i> , 2019, 6, 73-76.	0.1	1

#	ARTICLE	IF	CITATIONS
38	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
39	18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement. <i>Medicine (United States)</i> , 2019, 98, e14270.	0.4	1
40	Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. <i>Hematological Oncology</i> , 2019, 37, 22-26.	0.8	20
41	<i>Orbit.</i> , 2020, , 519-582.e10.		0
42	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 17-29.	0.6	197
43	Prevalence of <i>Chlamydia psittaci</i> , <i>Chlamydia pneumoniae</i> , and <i>Chlamydia trachomatis</i> Determined by Molecular Testing in Ocular Adnexa Lymphoma Specimens. <i>American Journal of Clinical Pathology</i> , 2020, 153, 427-434.	0.4	15
44	<i>Borrelia burgdorferi</i> in primary cutaneous lymphomas: a systematic review and meta-analysis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1379-1384.	0.4	16
45	First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. <i>Cancers</i> , 2020, 12, 3533.	1.7	4
46	How I treat MALT lymphoma: a subjective interpretation of the gospel according to Isaacson et al. <i>ESMO Open</i> , 2020, 5, e000812.	2.0	9
47	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. <i>Haematologica</i> , 2020, 105, e349-e354.	1.7	5
49	Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT) Tj ETQq0 0.0 rgBT /Overlock 10	0.8	16
50	Clinical efficacy of the modified <i>Helicobacter pylori</i> eradication therapy for <i>Helicobacter pylori</i> -negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis. <i>Chinese Medical Journal</i> , 2020, 133, 1337-1346.	0.9	7
51	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Cancers</i> , 2020, 12, 492.	1.7	7
52	Second Cancers in a Patient with Gastric MALT Lymphoma. <i>Case Reports in Medicine</i> , 2020, 2020, 1-4.	0.3	0
53	A Retrospective Analysis of Primary Gastrointestinal Non-Hodgkin Lymphomas: Clinical Features, Prognostic Factors and Treatment Outcomes. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5345-5352.	1.0	4
54	Putative role of marginal zone B cells in pathophysiological processes. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12920.	1.3	10
55	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	1.7	29
56	Myeloid-Derived Suppressor Cells and T17 Cells Contribute to the Development of Gastric MALT Lymphoma in <i>H. felis</i> -Infected Mice. <i>Frontiers in Immunology</i> , 2019, 10, 3104.	2.2	9

#	ARTICLE	IF	CITATIONS
57	Hepatitis C virus in MALT-lymphoma of the ocular adnexa. <i>Pathology Research and Practice</i> , 2020, 216, 152864.	1.0	8
58	Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 303-308.	1.5	1
59	<i>Hematopathology</i> , 2020, , 1729-2141.		0
60	Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) outside of clinical trials: Real-world data from the University of Vienna. <i>Hematological Oncology</i> , 2020, 38, 409-411.	0.8	3
61	Paraneoplastic cerebellar degeneration: initial presentation of mucosa-associated lymphoid tissue lymphoma in a patient with primary Sjögren's syndrome. <i>Chinese Medical Journal</i> , 2020, 133, 1005-1007.	0.9	1
62	Indicators for Malignant Transformation in Patients With Lymphoepithelial Lesion. <i>Journal of Oral and Maxillofacial Surgery</i> , 2021, 79, 836-844.	0.5	3
63	A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1414-1420.	0.4	5
64	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 827-839.	0.6	13
65	Long-Term Clinical Outcome and Predictive Factors for Relapse after Radiation Therapy in 145 Patients with Stage I Gastric B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type. <i>Cancers</i> , 2021, 13, 169.	1.7	2
66	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma). <i>Hematologic Malignancies</i> , 2021, , 93-115.	0.2	1
67	The Pillow Sign: Is It Always Benign?. <i>ACG Case Reports Journal</i> , 2021, 8, e00540.	0.2	2
68	Correlation between 18 F-FDG PET/CT semiquantitative parameters and Ki-67 expression in pulmonary mucosa-associated lymphoid tissue lymphoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 188-194.	0.9	4
69	Development and validation of a prognostic nomogram for gastric marginal zone lymphoma: a Surveillance, Epidemiology and End Results-based population study. <i>Future Oncology</i> , 2021, 17, 529-539.	1.1	2
70	Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 609512.	1.3	8
71	How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies. <i>Expert Review of Hematology</i> , 2021, 14, 391-399.	1.0	2
72	Multifocal Colonic Ulcerations: An Unusual Presentation of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>GE Portuguese Journal of Gastroenterology</i> , 0, , 1-5.	0.3	0
73	Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2021, 13, 2993.	1.7	9
74	Plan Quality Comparisons Between 3D-CRT, IMRT, and VMAT Based on 4D-CT for Gastric MALT Lymphoma. <i>Anticancer Research</i> , 2021, 41, 3941-3947.	0.5	3

#	ARTICLE	IF	CITATIONS
75	Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. European Journal of Cancer, 2021, 152, 129-138.	1.3	6
76	Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment. International Journal of Molecular Sciences, 2021, 22, 7372.	1.8	17
77	Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis. Frontiers in Oncology, 2021, 11, 609882.	1.3	4
78	Glycopeptidomics Analysis of a Cell Line Model Revealing Pathogenesis and Potential Marker Molecules for the Early Diagnosis of Gastric MALT Lymphoma. Frontiers in Cellular and Infection Microbiology, 2021, 11, 715454.	1.8	1
79	<i>Helicobacter pylori</i> eradication: Exploring its impacts on the gastric mucosa. World Journal of Gastroenterology, 2021, 27, 5152-5170.	1.4	12
80	Primary Nondural Central Nervous System Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type Mimicking CNS Inflammatory Diseases. Journal of Neuro pathology and Experimental Neurology, 2021, 80, 789-799.	0.9	4
81	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line <i>Helicobacter pylori</i> eradication. Blood, 2022, 139, 240-244.	0.6	22
82	Rituximab combined with entecavir for primary rectal mucosa-associated lymphoid tissue lymphoma: A case report. Asian Journal of Surgery, 2021, 44, 1583-1584.	0.2	0
83	Analysis of Chronic Kidney Disease After Radiation Therapy for Gastric/Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma. Advances in Radiation Oncology, 2021, 6, 100788.	0.6	1
84	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. Frontiers in Cellular and Infection Microbiology, 2021, 11, 686595.	1.8	3
85	What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110338.	1.4	6
86	Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. International Journal of Rheumatic Diseases, 2018, 21, 93-101.	0.9	5
87	Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the <i>MALT1</i> gene. World Journal of Gastroenterology, 2017, 23, 6155-6163.	1.4	9
88	Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature. World Journal of Hepatology, 2017, 9, 155.	0.8	14
89	Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma. Annals of Hematology, 2022, 101, 91-97.	0.8	4
90	Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin's lymphoma: a systematic review and meta-analysis. Cancer Cell International, 2021, 21, 524.	1.8	6
91	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. British Journal of Haematology, 2021, 192, 1020-1025.	1.2	1
95	The clinicopathological features of parotid lymphoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 2050-2057.	0.5	1

#	ARTICLE	IF	CITATIONS
97	Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma. <i>Scientific Reports</i> , 2021, 11, 18460.	1.6	1
98	Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis. <i>Scientific Reports</i> , 2021, 11, 22586.	1.6	3
100	Pulmonary MALT lymphoma associated with interstitial pulmonary disease. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101598.	0.2	2
101	The role of ¹⁸ F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>British Journal of Radiology</i> , 2022, 95, 20210635.	1.0	1
102	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2022, 14, 1005.	1.7	11
103	Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. <i>Cancers</i> , 2022, 14, 1742.	1.7	19
104	Indolent Nonprogressive Multifocal Choroidal Lymphoid Lesions. <i>Ophthalmology Retina</i> , 2022, 6, 957-962.	1.2	1
105	Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 1353-1361.	1.2	4
109	Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. <i>JCO Global Oncology</i> , 2022, 8, e2100265.	0.8	6
110	A novel prognostic nomogram for patients with extragastric mucosa-associated lymphoid tissue lymphoma: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 3407-3416.	1.3	1
111	Peripheral T-Cell Lymphoma of Urinary Bladder Presenting With Just Irritative Voiding Symptoms. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 133-137.	0.1	0
112	A Case of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in Buccal Mucosa. <i>Korean Society for Head and Neck Oncology</i> , 2022, 38, 49-52.	0.1	0
113	Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000-2015). <i>Radiotherapy and Oncology</i> , 2022, 173, 179-187.	0.3	7
114	Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. <i>Cancers</i> , 2022, 14, 3019.	1.7	7
115	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
116	Mucosa-associated lymphoid tissue of nasopharynx: A case report and literature review. <i>Radiology Case Reports</i> , 2022, 17, 2991-2995.	0.2	0
117	A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 2894-2907.	0.6	1
119	Primary malt-tracheal lymphoma: case report. <i>Siberian Journal of Oncology</i> , 2022, 21, 151-159.	0.1	0

#	ARTICLE	IF	CITATIONS
120	Rare primary rectal mucosa-associated lymphoid tissue lymphoma with curative resection by endoscopic submucosal dissection: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 7599-7608.	0.3	2
121	Thymic Extranodal Marginal-Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: Pathological Features, 18F-FDG PET/CT Findings and Prognosis in 12 Cases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
122	The Role of The Tumor Microbiome in Tumor Development and Its Treatment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	26
123	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. <i>Annals of Hematology</i> , 0, , .	0.8	0
124	Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	2
125	<sc>MRI-Based</sc> Radiomics Nomogram for Preoperative Differentiation Between Ocular Adnexal Lymphoma and Idiopathic Orbital Inflammation. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	1
126	Primary mucosa-associated lymphoid tissue lymphoma in fallopian tubes: A case report and literature review. <i>Medicine (United States)</i> , 2022, 101, e30228.	0.4	1
127	Salivary Gland Ultrasound in Primary Sjögren's Syndrome: Current and Future Perspectives. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 147-160.	0.8	10
128	Prospective Study of 4 Gy Radiotherapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma (FORMAL). <i>Cancers</i> , 2022, 14, 4274.	1.7	1
130	Primary pulmonary mucosa-associated lymphoid tissue lymphoma: A case report. <i>Radiology Case Reports</i> , 2022, 17, 4842-4846.	0.2	0
131	Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-7.	1.1	0
132	SNP-Target Genes Interaction Perturbing the Cancer Risk in the Post-GWAS. <i>Cancers</i> , 2022, 14, 5636.	1.7	8
133	First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma. <i>EJHaem</i> , 0, , .	0.4	0
134	MALT lymphoma of the head and neck: Surgery alone can be an option. <i>Oral Oncology</i> , 2023, 136, 106258.	0.8	2
135	Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Annals of Hematology</i> , 2023, 102, 359-367.	0.8	1
136	Case report: Primary intracranial mucosa-associated lymphoid tissue lymphoma presenting as two primary tumors involving the cavernous sinus and extra-axial dura, respectively. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
137	Hematologic imaging. , 2023, , 225-244.		0
138	<sc>Anti-CD40L</sc> therapy prevents the formation of precursor lesions to gastric B-cell <sc>MALT</sc> lymphoma in a mouse model. <i>Journal of Pathology</i> , 0, , .	2.1	1

#	ARTICLE	IF	CITATIONS
139	Peripheral B cells from patients with hepatitis C virus-associated lymphoma exhibit clonal expansion and an anergic-like transcriptional profile. <i>IScience</i> , 2023, 26, 105801.	1.9	1
140	Early Reâ€œcagâ€œnition: CagA-specific CD8+ T Cells Shape the Immune Response to <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2023, 164, 520-521.	0.6	0
141	Primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue lymphoma treated by laparoscopic partial hepatectomy: a case report. <i>Surgical Case Reports</i> , 2023, 9, .	0.2	0
142	Risk factors analysis and establishment of predictive nomogram of extranodal B-cell lymphoma of mucosal-associated lymphoid tissue. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2023, 27, 126-135.	0.6	0
143	Nomogram model predicting the overall survival for patients with primary gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 533-545.	0.8	0
144	Early gastric mucosa-associated lymphoid tissue lymphoma treated by endoscopic submucosal dissection. <i>Endoscopy</i> , 2023, 55, E543-E544.	1.0	1
145	Unusual Instance of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Confined to a Colonic Polyp. <i>Cureus</i> , 2023, , .	0.2	0
146	Primary Lymphoproliferative Lung Diseases: Imaging and Multidisciplinary Approach. <i>Diagnostics</i> , 2023, 13, 1360.	1.3	0
147	Magenlymphom. <i>Springer Reference Medizin</i> , 2023, , 1-6.	0.0	0
148	<i>Helicobacter pylori</i> infection. <i>Nature Reviews Disease Primers</i> , 2023, 9, .	18.1	93
156	Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 5219-5227.	0.8	1
157	<i>Cancer Epidemiology</i> . , 2023, , 1-43.		0
158	Anti-CD20 antibody treatment for B-cell malignancies. , 2024, , 31-75.		0
160	Neoplasms of the Pharynx. , 2023, , 532-641.e9.		0
172	Extranodales Marginalzonenlymphom des mukosaassoziierten lymphatischen Gewebes (MALT-Lymphom). , 2023, , 103-128.		0